LLY

1,021.33

-1%↓

JNJ

240.49

+0.49%↑

ABBV

220.27

-1.72%↓

NVS

159.73

+0.82%↑

MRK

118.57

+1.15%↑

LLY

1,021.33

-1%↓

JNJ

240.49

+0.49%↑

ABBV

220.27

-1.72%↓

NVS

159.73

+0.82%↑

MRK

118.57

+1.15%↑

LLY

1,021.33

-1%↓

JNJ

240.49

+0.49%↑

ABBV

220.27

-1.72%↓

NVS

159.73

+0.82%↑

MRK

118.57

+1.15%↑

LLY

1,021.33

-1%↓

JNJ

240.49

+0.49%↑

ABBV

220.27

-1.72%↓

NVS

159.73

+0.82%↑

MRK

118.57

+1.15%↑

LLY

1,021.33

-1%↓

JNJ

240.49

+0.49%↑

ABBV

220.27

-1.72%↓

NVS

159.73

+0.82%↑

MRK

118.57

+1.15%↑

Начало・Списък с акции・Celsion Corp

Celsion Corp

Отворен

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Ключови измерители
By Trading Economics
Служители	25

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+470.99% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	938K
Предишно отваряне	0
Предишно затваряне	0

Celsion Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.02.2026 г., 23:26 ч. UTC

Значими двигатели на пазара

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10.02.2026 г., 22:31 ч. UTC

Печалби

Correction to America Movil 4Q Profit Article

10.02.2026 г., 22:22 ч. UTC

Печалби

America Movil 4Q Profit Jumps on Lower Financial Costs

10.02.2026 г., 23:51 ч. UTC

Пазарно говорене

Печалби

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10.02.2026 г., 23:42 ч. UTC

Пазарно говорене

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10.02.2026 г., 23:40 ч. UTC

Пазарно говорене

Печалби

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10.02.2026 г., 23:21 ч. UTC

Пазарно говорене

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10.02.2026 г., 23:21 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

10.02.2026 г., 22:17 ч. UTC

Пазарно говорене

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10.02.2026 г., 22:15 ч. UTC

Печалби

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10.02.2026 г., 22:10 ч. UTC

Печалби

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10.02.2026 г., 22:10 ч. UTC

Печалби

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10.02.2026 г., 22:09 ч. UTC

Печалби

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10.02.2026 г., 22:09 ч. UTC

Печалби

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10.02.2026 г., 22:01 ч. UTC

Печалби

Intact Financial 4Q EPS C$5.24 >IFC.T

10.02.2026 г., 21:54 ч. UTC

Печалби

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10.02.2026 г., 21:53 ч. UTC

Печалби

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10.02.2026 г., 21:51 ч. UTC

Печалби

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10.02.2026 г., 21:51 ч. UTC

Печалби

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10.02.2026 г., 21:51 ч. UTC

Печалби

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10.02.2026 г., 21:51 ч. UTC

Печалби

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10.02.2026 г., 21:51 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10.02.2026 г., 21:50 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10.02.2026 г., 21:50 ч. UTC

Печалби

James Hardie Industries 3Q EPS 12c >JHX

10.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

10.02.2026 г., 21:50 ч. UTC

Печалби

James Hardie Industries 3Q Adj EPS 24c >JHX

10.02.2026 г., 21:49 ч. UTC

Печалби

James Hardie Industries 3Q Sales $1.24B >JHX

10.02.2026 г., 21:49 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10.02.2026 г., 21:48 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10.02.2026 г., 21:47 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Сравнение с други в отрасъла

Ценова промяна

Celsion Corp Прогноза

Ценова цел

By TipRanks

470.99% нагоре

12-месечна прогноза

Среден 18.5 USD 470.99%

Висок 25 USD

Нисък 12 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Celsion Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Celsion Corp през последните 3 месеца.

Финанси

Относно Celsion Corp

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.